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Abstract
Necroptosis is a regulated caspase-independent cell death pathway resulting in morphology
reminiscent of passive non-regulated necrosis. Several diverse structure classes of necroptosis
inhibitors have been reported to date, including a series of [1,2,3]thiadiazole benzylamide derivatives.
However, initial evaluation of mouse liver microsome stability indicated that this series of
compounds was rapidly degraded. A structure-activity relationship (SAR) study of the [1,2,3]
thiadiazole benzylamide series revealed that increased mouse liver microsome stability and increased
necroptosis inhibitory activity could be accomplished by replacement of the 4-cyclopropyl-[1,2,3]
thiadiazole with a 5-cyano-1-methylpyrrole. In addition, the SAR and the cellular activity profiles,
utilizing different cell types and necroptosis-inducing stimuli, of representative [1,2,3]thiadiazole
and pyrrole derivatives were very similar suggesting that the two compound series inhibit necroptosis
in the same manner.
Necroptosis is a regulated caspase-independent cell death pathway resulting in morphological
features reminiscent of passive non-regulated necrosis.1, 2 Necroptosis can be induced with
various stimuli (e.g. TNF-α and Fas ligand) and in a variety of cell types (e.g. monocytes,
fibroblasts, lymphocytes, macrophages, epithelial cells and neurons). Furthermore, it may
represent a significant contributor to and in some cases predominant mode of cellular demise
under pathological conditions involving excessive cell stress, rapid energy loss and massive
oxidative species generation, not conducive for highly energy-dependent processes such as
apoptosis. Discovery of regulated necrotic cell death mechanisms, such as necroptosis, raises
the possibility of implementing novel therapeutic intervention strategies for the treatment of
diseases where necrosis is known to play a prominent role, such as organ ischemia (i.e.
stroke3, myocardial infarction4 and retinal ischemia5), traumatic brain injury6, liver injury7,
cancer chemo/radiation therapy-induced necrosis8, acute necrotizing pancreatitis9 and
possibly some forms of neurodegeneration.10
To date several diverse structure classes of necroptosis inhibitors have been reported, including
hydantoin containing indole derivatives (i.e. 1),11 tricyclic derivatives (i.e. 2),12 substituted
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3H-thieno[2,3-d]pyrimidin-4-ones (i.e. 3),13 and [1,2,3]thiadiazole benzylamides (i.e. 4)14
(Figure 1). In addition, (±)-1 and its derivatives have demonstrated in vivo activity in the
temporary and permanent middle cerebral artery occlusion (MCAO) model of cerebral
ischemia1, in a mouse model of ischemia/reperfusion heart injury15 and in the controlled
cortical impact (CCI) model of traumatic brain injury (TBI).16 Structure-activity relationship
(SAR) studies leading to significant potency improvements for necrostatins have been reported
11 – 14, however, issues of bioavailability for these promising agents have not been previously
addressed, except for 1.11
In order to evaluate the in vivo pharmacology of other necroptosis inhibitors via preferred
administration routes (i.e. oral, intravenous, intraperitoneal or subcutaneous) they must possess
adequate metabolic stability, in addition to in vitro potency. One efficient and cost effective
method of assessing a compound’s metabolic stability is to measure its resistance to metabolism
over time in the presence of liver microsomes.17 Utilizing this technique with mouse liver
microsomes, compound 4, which inhibits necroptosis induced with TNF-α in FADD-deficient
variant of human Jurkat T cells with an EC50 value of 0.28 µM, demonstrated poor metabolic
stability with a half-life (t1/2) of 32.5 min and intrinsic clearance (CLint) of 42.6 ± 3.2 µL/min/
mg protein. Herein, we describe the results of a SAR study to optimize the mouse liver
microsome stability of this inhibitor series. In addition, we evaluated the cellular activity profile
of an optimized inhibitor utilizing different cell types and necroptosis-inducing stimuli.
3-Alkyl pyrrole derivatives were prepared according to the procedure outlined in Scheme
1.18 Glycine ethyl ester, 5, was treated with p-toluenesulfonyl chloride (Ts-Cl) to give 6, which
upon treatment with 4-diethylaminobutan-2-one in the presence of t-BuOK gave 7.
Dehydration with POCl3 yielded the dihydropyrrole derivative 8. Elimination in the presence
of sodium ethoxide generated pyrrole derivative 9. The pyrrole nitrogen was deprotonated with
sodium hydride and alkylated to give 10. The ester was hydrolyzed with aqueous KOH in
MeOH and then the corresponding acid 11 was converted to amide 12 using EDCI.
1-Alkyl pyrrole derivatives were prepared according to the procedure outlined in Scheme 2.
Methyl 2-pyrrolecarboxylate, 13, was deprotonated using sodium hydride and then alkylated
to give 14. The ester was hydrolyzed to give acid 15, which was coupled to a 2-chloro-6-
fluorobenzylamine utilizing EDCI to give amide 16. Regioselective bromination with NBS
gave 17. Finally, conversion of the aryl bromide to a nitrile was accomplished utilizing a
palladium-mediated coupling with zinc cyanide to give 18 in excellent yield.19
Alternatively, cyano- and halo-substituted pyrrole derivatives were prepared according to the
procedure outlined in Scheme 3. 1-Alkylpyrroles 14 were allowed to react with chlorosulfonyl
isocyanate to give two readily separable regioisomeric cyanopyrrole derivatives 19 and 20
(1:4).20 Each was converted the corresponding acid and then coupled with 2-chloro-6-
fluorobenzylamine to give 21 and 22, respectively. Methyl 2-pyrrolecarboxylate, 13, was also
regioselectively chlorinated with t-butyl hypochlorite to give 23.21 N-alkylation gave 24 and
subsequent ester hydrolysis yielded 25, which was coupled with 2-chloro-6-fluorobenzylamine
to give 26.
Finally, a sulfonamide pyrrole derivative was prepared according to the procedure outlined in
Scheme 4. N-methylpyrrole sulfonyl chloride derivative 27 was allowed to react with 2-
chloro-6-fluorobenzylamine to give 28. This material was treated with ammonia gas in the
presence of trimethylaluminum to give a mixture of amide 29 and nitrile 30.22 The isolated
amide 29 could be converted to nitrile 30 in the presence of phosphorus oxychloride.23
Evaluation of compounds 26, 30 and 31 – 50 (Table 1) for necroptosis inhibitory activity was
performed using a FADD-deficient variant of human Jurkat T cells treated with TNF-α as
previously described.1, 12 Utilizing these conditions the cells efficiently underwent
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necroptosis, which was completely and selectively inhibited by 1 (EC50 = 0.050 µM). For
EC50 value determinations, cells were treated with 10 ng/mL of human TNF-α in the presence
of increasing concentration of test compounds for 24 h followed by ATP-based viability
assessment. Microsome stability was determined in pooled mouse liver microsomes.24 The
results of the biological studies are shown in Table 2.
The heterocyclic ring in 4 was presumed to be most likely responsible for the compound’s lack
of metabolic stability. To test this hypothesis, a related derivative that replaced the 4-alkyl-
[1,2,3]thiadiazole with a 2-methylphenyl (i.e. 51) was prepared. This compound was devoid
of necroptosis inhibitory activity, but demonstrated a significant improvement in mouse
microsome stability with a t1/2 of 194 min and CLint of 7.13 ± 7.3 µL/min/mg protein. Based
on these findings other surrogates for the [1,2,3]thiadiazole were sought that would retain
necroptosis inhibitory activity.
Replacement of the 4-cyclopropyl-[1,2,3]thiadiazole with a pyrrole (31), a 3-alkylpyrrole
(32) or 1,3-dialkylpyrroles (33 and 34) resulted in significant decreases in necroptosis
inhibitory activity compared with 4. However, replacement with 1-methyl- or 1-
isopropylpyrrole (35 and 36) resulted in a less significant decrease in activity suggesting that
N-alkylpyrroles may present a possible replacement. However, 35 demonstrated poor mouse
microsome stability presumably due to the electron-rich nature of the pyrrole ring. Increasing
the size of the alkyl group (37 and 38) resulted in further decreases in necroptosis inhibitory
activity. In addition, a tertiary amide (39) was not tolerated. This result was consistent with the
SAR previously established for the [1,2,3]thiadiazole series.14 Introduction of a methyl group
on the benzylic position of the amide (40) resulted in a decrease in necroptosis inhibitory
activity. However, again consistent with the SAR for the [1,2,3]thiadiazole series, all of the
activity resided with the (S)-enantiomer (41 vs. 42) and large substituents on the benzylic
carbon (43) were not tolerated. Addition of electron-withdrawing groups to the 5-position of
the pyrrole that would render it less electron rich, were tolerated (26 and 44), with nitrile
(45) being best. In the case of 26 mouse microsome stability was worst compared with 4.
However, 45 showed a slight improvement in stability. Interestingly, introduction of the nitrile
to the 4-position of the pyrrole (49 and 50) eliminated necroptosis inhibitory activity. Increasing
the size of the alkyl group on the 1-poistion of the pyrrole (46 and 47) was also detrimental to
necroptosis inhibitory activity. However, introduction of a (S)-methyl substituent to the
benzylic amide position of the 5-cyano-1-methylpyrrole (48)25 resulted in a significant
increase in both necroptosis inhibitory activity (EC50 = 92 nM) and mouse microsome stability
(t1/2 = 236 min and in CLint of 5.9 ± 2.5 µL/min/mg protein). Finally, sulfonamide 30 was
found to be inactive as a necroptosis inhibitor further demonstrating the importance of the
secondary amide functionality.
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Although the precise mechanism of necroptosis inhibition by the [1,2,3]thiadiazole series is
not currently known, it has shown an unique inhibitory profile compared to (±)-1 and 2 when
evaluated in different cell types and utilizing different necroptosis-inducing stimuli.12, 14
Therefore, a similar analysis was conducted comparing 48 with (±)-1 and 4 (Figure 2). The
cellular activity profiles for the [1,2,3]thiadiazole and pyrrole inhibitors were very similar
suggesting that the two compound series inhibit necroptosis in the same manner and that the
5-cyano-1-methylpyrrole in 48 acts as a bioisostere for the 4-cyclopropyl-[1,2,3]thiadiazole in
4.26 Furthermore, both compounds demonstrated a very different profile compared to (±)-1
suggesting that they posses a distinct mode of necroptosis inhibition.
In conclusion, 5-cyano-1-methylpyrrole was found to be an excellent surrogate for the 4-
cyclopropyl-[1,2,3]thiadiazole in 4 resulting in 48, which demonstrated significantly increased
necroptosis inhibitory activity and has improved mouse microsome stability. The SAR of the
pyrrole derivatives for necroptosis inhibition paralleled the [1,2,3]thiadiazoles in many
respects, including the requirement for a secondary amide and when a benzylic methyl was
present all of the necroptosis activity resided with the (S)-enantiomer. Finally, cellular activity
profiles of the 5-cyano-1-methylpyrrole 48 and the [1,2,3]thiadiazole 4 utilizing different cell
types and necroptosis-inducing stimuli were very similar suggesting that the two compound
series inhibit necroptosis in the same manner and are distinct from 1 and 2. Studies are currently
underway to further evaluate 5-cyano-1-methylpyrrole necroptosis inhibitors in animal models
of disease where necroptosis is likely to play a substantial role (i.e. liver injury) and to
investigate the mechanism of necroptosis inhibition by these derivatives.
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Figure 1.
Necrostatins
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Figure 2.
Cell type/stimulus specific activities of necrostatins. FADD-deficient Jurkat, L929 and mouse
adult lung fibroblast cells were treated for 24 hr with 10 ng/mL human TNF-α and/or 100 µM
zVAD.fmk as indicated in the presence of 30 µM of necrostatin (±)-1, 4 or 48. Cell viability
was determined using an ATP-based assessment method. Values were normalized to cells
treated with necrostatins in the absence of necroptotic stimulus, which were set as 100%
viability. Error bars reflect standard deviation values (N = 2).
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Scheme 1.
(a) Py, TsCl, CH2Cl2, rt, 6 h; (b) 4-diethylaminobutan-2-one, t-BuOK, t-BuOH, THF, rt, 2 d;
(c) POCl3, Py, rt, 18 h, (45%, over three steps); (d) NaOEt, EtOH rt, 5 h, (82%); (e) NaH, DMF,
R1I, rt, 12 h, (60–90%); (f) KOH, MeOH, H2O, 50 °C, 12 h,; (g) EDCI, HOBt, ArCH2NH2,
DMF, rt, 12 h, (50–85%, over two steps).
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Scheme 2.
(a) NaH, DMF, R1I, rt, 12 h, (80–95%); (b) KOH, MeOH, H2O, rt, 8 h; (c) EDCI, HOBt, ArCH
(R)NH2, DMF, rt, 12 h, (50–85%, two steps); (d) NBS, MeOH, THF, rt, 6 h, (75%); (e) Zn
(CN)2, Pd(PPh3)4, DMF, 95 °C, 6 h, (85%).
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Scheme 3.
(a) ClSO2NCO, CH3CN, rt, 2.5 h (82%); (b); (c) EDCI, HOBt, ArCH(R)NH2, DMF, rt, 12 h,
(50–85%, over two steps); (d) t-Butyl hypochlorite, CCl4, rt, 2 d, (50%); (e) NaH, DMF, MeI,
rt, 12 h, (80–95%); (f) KOH, MeOH, H2O, rt, 6 h (used without purification).
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Scheme 4.
(a) Py, CH2Cl2, rt, 6 h, (95%); (b) 2.0 M AlMe3 in hexane, NH3 gas, 125 °C, PhCl, 2 d; (c)
POCl3, Et3N, CHCl3, rt, 2 h (80% over two steps).
Teng et al. Page 12
Bioorg Med Chem Lett. Author manuscript; available in PMC 2009 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Teng et al. Page 13
Ta
bl
e 
1
Py
rr
ro
le
 a
m
id
e 
de
riv
at
iv
es
 p
re
pa
re
d 
fo
r 
in
hi
bi
tio
n 
of
 n
ec
ro
pt
os
is
 in
 F
A
D
D
-d
ef
ic
ie
nt
 J
ur
ka
t T
 c
el
ls
 tr
ea
te
d 
w
ith
 T
N
F-
α 
an
d 
m
ou
se
m
ic
ro
so
m
e 
st
ab
ili
ty
 te
st
in
g.
C
om
po
un
d
R
1
R
2
R
3
R
4
R
5
R
6
26
M
e
C
l
H
H
H
H
31
H
H
H
H
H
H
32
H
H
H
M
e
H
H
33
M
e
H
H
M
e
H
H
34
i-P
r
H
H
M
e
H
H
35
M
e
H
H
H
H
H
36
i-P
r
H
H
H
H
H
37
B
n
H
H
H
H
H
38
C
H
(M
e)
Ph
H
H
H
H
H
39
M
e
H
H
H
M
e
H
40
i-P
r
H
H
H
H
(±
)-
M
e
41
i-P
r
H
H
H
H
(S
)-
M
e
42
i-P
r
H
H
H
H
(R
)-
M
e
43
i-P
r
H
H
H
H
(±
)-
n-
B
u
44
Et
B
r
H
H
H
H
45
M
e
C
N
H
H
H
H
46
Et
C
N
H
H
H
H
47
i-P
r
C
N
H
H
H
H
48
M
e
C
N
H
H
H
(S
)-
M
e
49
M
e
H
C
N
H
H
H
50
i-P
r
H
C
N
H
H
H
Bioorg Med Chem Lett. Author manuscript; available in PMC 2009 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Teng et al. Page 14
Table 2
EC50 determinations for necroptosis inhibition in FADD-deficient Jurkat T cells treated with TNF-α and mouse
microsome stability values.
Compound EC50 (µM)
a t1/2 (min) CLint (µL/min/mg protein)
4 0.28 32.5 42.6 ± 3.2
26 0.74 15.4 89.8 ± 3.0
30 > 20 --- ---
31 > 20 --- ---
32 4.9 --- ---
33 > 20 --- ---
34 7.8 --- ---
35 0.90 17.2 80.6 ± 4.4
36 0.44 --- ---
37 > 20 --- ---
38 > 20 --- ---
39 > 20 --- ---
40 2.1 --- ---
41 0.52 --- ---
42 > 20 --- ---
43 > 20 --- ---
44 2.4 --- ---
45 0.34 42.3 32.8 ± 2.2
46 1.9 --- ---
47 1.4 --- ---
48 0.092 236 5.9 ± 2.5
49 > 20 --- ---
50 > 20 --- ---
a
Standard deviation < 10%.
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